Mandate

Vinge advised Valneva SE in connection with its acquisition of Crucell Sweden AB

January 18, 2016

Vinge, in cooperation with Dechert LLP as lead legal advisor, advised Valneva SE in connection with its acquisition of Crucell Sweden AB, the Nordics vaccine distribution business of the seller (Crucell Holland B.V.) and all assets, licenses and privileges related to Dukoral®, a vaccine against cholera and, in some countries, diarrhea caused by ETEC. Valneva is a Lyon based biotechnology company listed at Euronext Paris and at the Vienna stock exchange. The consideration amounted to € 45 million and the acquisition was completed on 9 February 2015.

Vinge advised Valneva on Swedish law matters. Vinge’s team consists of M&A partner Peter Sundgren, associates Johanna Wiberg and Kajsa Hallner (M&A), Anders Morén and Josefin Larsson (banking & finance), and Amanda Knutsson and David Andersson (capital markets).

Related

Vinge advises Pricer in connection with Vusion’s public takeover offer

On 17 November 2026, VusionGroup S.A., a French public limited company listed on Euronext Paris, announced a recommended public takeover offer to the shareholders of Pricer Aktiebolag (publ) to acquire all shares in Pricer for a consideration of SEK 6.00 per share. The offer values all shares in Pricer at approximately SEK 980.4 million.
November 20, 2026

Vinge has advised Rite Ventures in connection with sale of shares in Qliro AB (publ)

Vinge has advised Rite Ventures in connection with the sale of shares in Qliro AB (publ) to Svea Bank AB (publ).
November 19, 2026

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026